Home LiteratureArticle Details
PMID: 11176129 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study.

Annals of surgery ·Vol. 233 ·No. 2 ·2001-02-00 ·Pages 227-35

Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J

Abstract

To evaluate the correlation between serum vascular endothelial growth factor (VEGF) level and the clinicopathologic features in patients with hepatocellular carcinoma (HCC). VEGF is an important angiogenic factor regulating tumor angiogenesis. A high serum VEGF level has been shown to be associated with tumor progression and metastasis in several human cancers, but its significance in HCC is unclear. The correlation between serum VEGF level and tumor pathologic features in patients with HCC has not been studied before. Preoperative serum samples and tumor specimens were prospectively collected in 100 patients undergoing resection of HCC. Serum VEGF level was measured by enzyme-linked immunosorbent assay, and tumor VEGF expression was assessed by immunohistochemical study. Histopathologic examination was performed by a pathologist without prior knowledge of the serum VEGF level or tumor VEGF expression. Preoperative serum VEGF levels ranged from 15 to 1,789 pg/mL (median 269). When serum VEGF levels were compared between groups categorized by different clinicopathologic variables, significant correlation was found between a high serum VEGF level and absence of tumor capsule, presence of intrahepatic metastasis, presence of microscopic venous invasion, and advanced stage. There was a positive correlation between the serum VEGF level and tumor expression of VEGF as well as platelet count. When the 75th percentile serum VEGF level (500 pg/mL) was used as a cutoff level, the frequency of venous invasion in patients with a high serum VEGF level was significantly greater compared with patients with a low serum VEGF level. By multivariate analysis, a serum VEGF level of more than 500 pg/mL and tumor size more than 5 cm were independent preoperative factors predictive of microscopic venous invasion. During a median follow-up of 11.6 months, 48% of patients with a serum VEGF level of more than 500 pg/mL and 27% of those with a serum VEGF level of 500 pg/mL or less developed postoperative recurrence. These results show that a high preoperative serum VEGF level is a predictor of microscopic venous invasion in HCC, suggesting that the serum VEGF level may be useful as a biologic marker of tumor invasiveness and a prognostic factor in HCC.

MeSH Terms
Adult Aged Carcinoma, Hepatocellular/blood,blood supply,pathology Endothelial Growth Factors/blood Female Humans Immunohistochemistry Liver Neoplasms/blood,blood supply,pathology Lymphokines/blood Male Middle Aged Neoplasm Invasiveness Neovascularization, Pathologic Platelet Count Prospective Studies Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors
Chemicals
Endothelial Growth Factors Lymphokines Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Poon R T
Centre of Liver Diseases, Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China. poontp@hkucc.hku.hk
Ng I O
Lau C
Zhu L X
Yu W C
Lo C M
Fan S T
Wong J
References (47)
47 references, click to expand
  1. Lack of intrahepatic recurrence of hepatocellular carcinoma by temporary portal venous embolization with starch microspheres.
    Surgery. 1989 Feb;105(2 Pt 1):188-91 PMID: 2536966
  2. Preoperative chemoembolization of hepatocellular carcinoma: a comparative study.
    Arch Surg. 1998 Jul;133(7):767-72 PMID: 9688007
  3. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction.
    Cancer Metastasis Rev. 1990 Nov;9(3):171-4 PMID: 1705485
  4. Hepatic resection versus transplantation for hepatocellular carcinoma.
    Ann Surg. 1991 Sep;214(3):221-8; discussion 228-9 PMID: 1656903
  5. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma.
    Gastroenterology. 1993 Aug;105(2):488-94 PMID: 8392955
  6. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.
    Cancer Res. 1993 Oct 1;53(19):4727-35 PMID: 8402650
  7. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma.
    Am J Surg. 1995 Jan;169(1):28-34; discussion 34-5 PMID: 7817995
  8. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.
    Hum Pathol. 1995 Jan;26(1):86-91 PMID: 7821921
  9. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.
    Cancer Res. 1995 Sep 15;55(18):3964-8 PMID: 7664263
  10. Constitutive expression of the thrombopoietin gene in a human hepatoma cell line.
    Biochem Biophys Res Commun. 1995 Dec 14;217(2):475-81 PMID: 7503724
  11. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma.
    Cancer. 1996 Mar 1;77(5):858-63 PMID: 8608475
  12. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer.
    Surgery. 1996 Mar;119(3):333-9 PMID: 8619189
  13. Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments.
    Cancer. 1996 May 15;77(10):2022-31 PMID: 8640665
  14. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor.
    Hepatology. 1996 Mar;23(3):455-64 PMID: 8617424
  15. Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients.
    Cancer. 1995 Dec 15;76(12):2443-8 PMID: 8625069
  16. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma.
    Cancer Res. 1996 Jul 1;56(13):3004-9 PMID: 8674055
  17. Tumor angiogenesis: the pivotal role of vascular endothelial growth factor.
    World J Urol. 1996;14(3):166-74 PMID: 8806195
  18. Vascular endothelial growth factor serum concentrations in ovarian cancer.
    Obstet Gynecol. 1998 Sep;92(3):360-3 PMID: 9721770
  19. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma.
    Hum Pathol. 1998 Sep;29(9):986-91 PMID: 9744316
  20. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation.
    Ann Intern Med. 1998 Oct 15;129(8):643-53 PMID: 9786813
  21. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome.
    Ann Surg. 1998 Oct;228(4):479-90 PMID: 9790338
  22. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients.
    Clin Cancer Res. 1996 May;2(5):821-6 PMID: 9816236
  23. Serum vascular endothelial growth factor is often elevated in disseminated cancer.
    Clin Cancer Res. 1997 May;3(5):647-51 PMID: 9815732
  24. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
    Cancer. 1999 Jan 1;85(1):178-87 PMID: 9921991
  25. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer.
    Urology. 1999 Feb;53(2):302-7 PMID: 9933044
  26. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors.
    Ann Surg. 1999 Feb;229(2):216-22 PMID: 10024103
  27. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.
    Br J Cancer. 1999 May;80(5-6):892-7 PMID: 10360671
  28. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.
    Cancer. 1954 May;7(3):462-503 PMID: 13160935
  29. Recurrence of hepatocellular carcinoma after surgery.
    Br J Surg. 1996 Sep;83(9):1219-22 PMID: 8983610
  30. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression.
    Cancer. 1997 Jan 15;79(2):206-13 PMID: 9010092
  31. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.
    Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 PMID: 9012841
  32. Is hepatocellular carcinoma in cirrhosis an actual indication for liver transplantation?
    Transplant Proc. 1997 Feb-Mar;29(1-2):492-4 PMID: 9123098
  33. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study.
    Hum Pathol. 1997 Jun;28(6):698-703 PMID: 9191004
  34. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.
    Br J Cancer. 1997;76(2):238-43 PMID: 9231925
  35. Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma.
    J Cancer Res Clin Oncol. 1997;123(7):383-7 PMID: 9260590
  36. Halting angiogenesis suppresses carcinoma cell invasion.
    Nat Med. 1997 Nov;3(11):1222-7 PMID: 9359696
  37. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.
    Blood. 1997 Oct 15;90(8):3167-72 PMID: 9376599
  38. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma.
    J Hepatol. 1997 Nov;27(5):854-61 PMID: 9382973
  39. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis.
    Ann Surg. 1997 Dec;226(6):688-701; discussion 701-3 PMID: 9409568
  40. Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer.
    Urology. 1998 Feb;51(2):327-32 PMID: 9495722
  41. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.
    Br J Cancer. 1998 Mar;77(6):956-64 PMID: 9528841
  42. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer.
    Int J Cancer. 1998 Apr 17;79(2):144-6 PMID: 9583728
  43. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma.
    J Thorac Cardiovasc Surg. 1998 May;115(5):1007-14 PMID: 9605068
  44. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma.
    J Exp Clin Cancer Res. 1998 Mar;17(1):13-7 PMID: 9646228
  45. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma.
    J Gastroenterol. 1998 Jun;33(3):376-82 PMID: 9658317
  46. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.
    Thromb Haemost. 1998 Jul;80(1):171-5 PMID: 9684805
  47. Significance of transcatheter chemoembolization combined with surgical resection for hepatocellular carcinomas.
    Cancer Chemother Pharmacol. 1989;23 Suppl:S90-5 PMID: 2538272
Article Info
Journal
Annals of surgery
Abbr.
Ann Surg
ISSN
0003-4932
Published
2001-02-00
Pages
227-35
Language
English
Region
United States
NLM ID
0372354
PMCID
PMC1421205
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com